Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis

Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1984-12, Vol.54 (12), p.2927-2935
Hauptverfasser: Hehlmann, Rüdiger, Erfle, Volker, Schetters, Hartmut, Luz, Arne, Rohmer, Heike, Schreiber, Martin A., Pralle, Hans, Essers, Ursula, Weber, Walter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2935
container_issue 12
container_start_page 2927
container_title Cancer
container_volume 54
creator Hehlmann, Rüdiger
Erfle, Volker
Schetters, Hartmut
Luz, Arne
Rohmer, Heike
Schreiber, Martin A.
Pralle, Hans
Essers, Ursula
Weber, Walter
description Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detected both in leukemic and in nonleukemic sera.23 In a further analysis of these data, the prognostic significance of SiSVgp70 related AG and IC indicates an unfavorable clinical course and a shorter survival time in acute leukemias (AL) and in chronic myelogenous leukemia in blast crisis (CML‐BC). Survival data of 56 of 64 patients tested were analyzed (38 patients with AL and 18 patients with CML‐BC). Patients with AL whose sera were positive for SiSVgp70 realted AG and IC had a median survival time of 9.5 months after diagnosis versus 16 months for patients negative for such AG and IC. This difference in survival time was more pronounced for patients with acute nonlymphocytic leukemia (ANLL) (6.5 versus 19 months). The difference in survival between SiSVgp70 related AG‐ and IC‐negative and positive groups as tested by life table analysis (log‐rank test) is significant (P < 0.05). Patients with AL of the AG‐ and/or IC‐positive group had fewer complete remissions. Patients who had no remissions belong to the AG‐ and/or IC‐positive group (P = 0.06). Patients with CML‐BC whose sera were positive for SiSVgp70 related AG and/or IC had a median survival time of 2 months after diagnosis versus 7 months for patients with sera negative for such AG and IC. As tested by long‐rank test, survival curves between the two groups are significantly different (P < 0.05). These findings suggest that SiSVgp70 related AG and IC may play an important role in the course of acute leukemia and can provide useful prognostic information.
doi_str_mv 10.1002/1097-0142(19841215)54:12<2927::AID-CNCR2820541219>3.0.CO;2-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81339959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81339959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5019-b7dfb718acfb431dc5afe8e84bd4a140675abc1ac8e3c3eeec0e041a629dfe853</originalsourceid><addsrcrecordid>eNqVkd2q1DAUhYsox_HoIwi5ENGLjvlpps0owtDjz8DBAY-KF0JI091ONG3GpFX7jL6UGWcc1AvBq7Czvr1YyUqSC4LnBGP6iGCRp5hk9AERRUYo4Q95tiT0CRU0Xy5X64u0fFW-pgXFfC-Lp2yO5-XmMU3ZtWR2Wr-ezDDGRcoz9v5mciuEj3HMKWdnydkCCyYKPku-r_rBtNAHpPoaaeP1aNVg-haZrht7QNp1OwvfICAPUYEaDQ4NW0A7b7o4x-vBuy_GK4taO2m3824A06Mrc_Wu3eV4idZ9bbQanA_INQiUtxPqnB-UNcOEIrodO9UjpcdoZ2H8BJ1Rx0Bb73qjUTeBdTGmG8NvRFytrAoD0t4EE24nNxplA9w5nufJ2-fP3pQv08vNi3W5ukw1x0SkVV43VU4KpZsqY6TWXDVQQJFVdaZIhhc5V5UmShfANAMAjQFnRC2oqCPI2Xly_-Abn_p5hDDIzgQN1qoeYkBZEMaE4CKCHw6g9i4ED438-Wl-kgTLfddyX5bclyV_dS15JgmV-66ljF3LP7uWTGJZbiSVLNrfPeYYqw7qk_mx3KjfO-oqaGUbr3ptwgkrBOeCk4i1B-yrsTD9Z8R_JvxLYT8Aybza_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>81339959</pqid></control><display><type>article</type><title>Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Hehlmann, Rüdiger ; Erfle, Volker ; Schetters, Hartmut ; Luz, Arne ; Rohmer, Heike ; Schreiber, Martin A. ; Pralle, Hans ; Essers, Ursula ; Weber, Walter</creator><creatorcontrib>Hehlmann, Rüdiger ; Erfle, Volker ; Schetters, Hartmut ; Luz, Arne ; Rohmer, Heike ; Schreiber, Martin A. ; Pralle, Hans ; Essers, Ursula ; Weber, Walter</creatorcontrib><description>Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detected both in leukemic and in nonleukemic sera.23 In a further analysis of these data, the prognostic significance of SiSVgp70 related AG and IC indicates an unfavorable clinical course and a shorter survival time in acute leukemias (AL) and in chronic myelogenous leukemia in blast crisis (CML‐BC). Survival data of 56 of 64 patients tested were analyzed (38 patients with AL and 18 patients with CML‐BC). Patients with AL whose sera were positive for SiSVgp70 realted AG and IC had a median survival time of 9.5 months after diagnosis versus 16 months for patients negative for such AG and IC. This difference in survival time was more pronounced for patients with acute nonlymphocytic leukemia (ANLL) (6.5 versus 19 months). The difference in survival between SiSVgp70 related AG‐ and IC‐negative and positive groups as tested by life table analysis (log‐rank test) is significant (P &lt; 0.05). Patients with AL of the AG‐ and/or IC‐positive group had fewer complete remissions. Patients who had no remissions belong to the AG‐ and/or IC‐positive group (P = 0.06). Patients with CML‐BC whose sera were positive for SiSVgp70 related AG and/or IC had a median survival time of 2 months after diagnosis versus 7 months for patients with sera negative for such AG and IC. As tested by long‐rank test, survival curves between the two groups are significantly different (P &lt; 0.05). These findings suggest that SiSVgp70 related AG and IC may play an important role in the course of acute leukemia and can provide useful prognostic information.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19841215)54:12&lt;2927::AID-CNCR2820541219&gt;3.0.CO;2-3</identifier><identifier>PMID: 6093985</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Acute Disease ; Adolescent ; Adult ; Aged ; AIDS/HIV ; Antigen-Antibody Complex - analysis ; Antigens, Viral - analysis ; Biological and medical sciences ; Hematologic and hematopoietic diseases ; Humans ; Leukemia - immunology ; Leukemia - mortality ; Leukemia - therapy ; Leukemia, Myeloid - immunology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Middle Aged ; Retroviridae - immunology ; Sarcoma Virus, Woolly Monkey - immunology ; Viral Envelope Proteins - immunology</subject><ispartof>Cancer, 1984-12, Vol.54 (12), p.2927-2935</ispartof><rights>Copyright © 1984 American Cancer Society</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5019-b7dfb718acfb431dc5afe8e84bd4a140675abc1ac8e3c3eeec0e041a629dfe853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8955951$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6093985$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hehlmann, Rüdiger</creatorcontrib><creatorcontrib>Erfle, Volker</creatorcontrib><creatorcontrib>Schetters, Hartmut</creatorcontrib><creatorcontrib>Luz, Arne</creatorcontrib><creatorcontrib>Rohmer, Heike</creatorcontrib><creatorcontrib>Schreiber, Martin A.</creatorcontrib><creatorcontrib>Pralle, Hans</creatorcontrib><creatorcontrib>Essers, Ursula</creatorcontrib><creatorcontrib>Weber, Walter</creatorcontrib><title>Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detected both in leukemic and in nonleukemic sera.23 In a further analysis of these data, the prognostic significance of SiSVgp70 related AG and IC indicates an unfavorable clinical course and a shorter survival time in acute leukemias (AL) and in chronic myelogenous leukemia in blast crisis (CML‐BC). Survival data of 56 of 64 patients tested were analyzed (38 patients with AL and 18 patients with CML‐BC). Patients with AL whose sera were positive for SiSVgp70 realted AG and IC had a median survival time of 9.5 months after diagnosis versus 16 months for patients negative for such AG and IC. This difference in survival time was more pronounced for patients with acute nonlymphocytic leukemia (ANLL) (6.5 versus 19 months). The difference in survival between SiSVgp70 related AG‐ and IC‐negative and positive groups as tested by life table analysis (log‐rank test) is significant (P &lt; 0.05). Patients with AL of the AG‐ and/or IC‐positive group had fewer complete remissions. Patients who had no remissions belong to the AG‐ and/or IC‐positive group (P = 0.06). Patients with CML‐BC whose sera were positive for SiSVgp70 related AG and/or IC had a median survival time of 2 months after diagnosis versus 7 months for patients with sera negative for such AG and IC. As tested by long‐rank test, survival curves between the two groups are significantly different (P &lt; 0.05). These findings suggest that SiSVgp70 related AG and IC may play an important role in the course of acute leukemia and can provide useful prognostic information.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>AIDS/HIV</subject><subject>Antigen-Antibody Complex - analysis</subject><subject>Antigens, Viral - analysis</subject><subject>Biological and medical sciences</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemia - immunology</subject><subject>Leukemia - mortality</subject><subject>Leukemia - therapy</subject><subject>Leukemia, Myeloid - immunology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Retroviridae - immunology</subject><subject>Sarcoma Virus, Woolly Monkey - immunology</subject><subject>Viral Envelope Proteins - immunology</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkd2q1DAUhYsox_HoIwi5ENGLjvlpps0owtDjz8DBAY-KF0JI091ONG3GpFX7jL6UGWcc1AvBq7Czvr1YyUqSC4LnBGP6iGCRp5hk9AERRUYo4Q95tiT0CRU0Xy5X64u0fFW-pgXFfC-Lp2yO5-XmMU3ZtWR2Wr-ezDDGRcoz9v5mciuEj3HMKWdnydkCCyYKPku-r_rBtNAHpPoaaeP1aNVg-haZrht7QNp1OwvfICAPUYEaDQ4NW0A7b7o4x-vBuy_GK4taO2m3824A06Mrc_Wu3eV4idZ9bbQanA_INQiUtxPqnB-UNcOEIrodO9UjpcdoZ2H8BJ1Rx0Bb73qjUTeBdTGmG8NvRFytrAoD0t4EE24nNxplA9w5nufJ2-fP3pQv08vNi3W5ukw1x0SkVV43VU4KpZsqY6TWXDVQQJFVdaZIhhc5V5UmShfANAMAjQFnRC2oqCPI2Xly_-Abn_p5hDDIzgQN1qoeYkBZEMaE4CKCHw6g9i4ED438-Wl-kgTLfddyX5bclyV_dS15JgmV-66ljF3LP7uWTGJZbiSVLNrfPeYYqw7qk_mx3KjfO-oqaGUbr3ptwgkrBOeCk4i1B-yrsTD9Z8R_JvxLYT8Aybza_Q</recordid><startdate>19841215</startdate><enddate>19841215</enddate><creator>Hehlmann, Rüdiger</creator><creator>Erfle, Volker</creator><creator>Schetters, Hartmut</creator><creator>Luz, Arne</creator><creator>Rohmer, Heike</creator><creator>Schreiber, Martin A.</creator><creator>Pralle, Hans</creator><creator>Essers, Ursula</creator><creator>Weber, Walter</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19841215</creationdate><title>Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis</title><author>Hehlmann, Rüdiger ; Erfle, Volker ; Schetters, Hartmut ; Luz, Arne ; Rohmer, Heike ; Schreiber, Martin A. ; Pralle, Hans ; Essers, Ursula ; Weber, Walter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5019-b7dfb718acfb431dc5afe8e84bd4a140675abc1ac8e3c3eeec0e041a629dfe853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>AIDS/HIV</topic><topic>Antigen-Antibody Complex - analysis</topic><topic>Antigens, Viral - analysis</topic><topic>Biological and medical sciences</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemia - immunology</topic><topic>Leukemia - mortality</topic><topic>Leukemia - therapy</topic><topic>Leukemia, Myeloid - immunology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Retroviridae - immunology</topic><topic>Sarcoma Virus, Woolly Monkey - immunology</topic><topic>Viral Envelope Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hehlmann, Rüdiger</creatorcontrib><creatorcontrib>Erfle, Volker</creatorcontrib><creatorcontrib>Schetters, Hartmut</creatorcontrib><creatorcontrib>Luz, Arne</creatorcontrib><creatorcontrib>Rohmer, Heike</creatorcontrib><creatorcontrib>Schreiber, Martin A.</creatorcontrib><creatorcontrib>Pralle, Hans</creatorcontrib><creatorcontrib>Essers, Ursula</creatorcontrib><creatorcontrib>Weber, Walter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hehlmann, Rüdiger</au><au>Erfle, Volker</au><au>Schetters, Hartmut</au><au>Luz, Arne</au><au>Rohmer, Heike</au><au>Schreiber, Martin A.</au><au>Pralle, Hans</au><au>Essers, Ursula</au><au>Weber, Walter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1984-12-15</date><risdate>1984</risdate><volume>54</volume><issue>12</issue><spage>2927</spage><epage>2935</epage><pages>2927-2935</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Human sera contain antigens and also circulating immune complexes that are related to the primate retroviral envelope glycoprotein gp70 of simian sarcoma/simian sarcoma associated virus (SiSV) and of gibbon ape leukemia virus (GaLV). SiSVgp70 related antigens (AG) and immune complexes (IC) are detected both in leukemic and in nonleukemic sera.23 In a further analysis of these data, the prognostic significance of SiSVgp70 related AG and IC indicates an unfavorable clinical course and a shorter survival time in acute leukemias (AL) and in chronic myelogenous leukemia in blast crisis (CML‐BC). Survival data of 56 of 64 patients tested were analyzed (38 patients with AL and 18 patients with CML‐BC). Patients with AL whose sera were positive for SiSVgp70 realted AG and IC had a median survival time of 9.5 months after diagnosis versus 16 months for patients negative for such AG and IC. This difference in survival time was more pronounced for patients with acute nonlymphocytic leukemia (ANLL) (6.5 versus 19 months). The difference in survival between SiSVgp70 related AG‐ and IC‐negative and positive groups as tested by life table analysis (log‐rank test) is significant (P &lt; 0.05). Patients with AL of the AG‐ and/or IC‐positive group had fewer complete remissions. Patients who had no remissions belong to the AG‐ and/or IC‐positive group (P = 0.06). Patients with CML‐BC whose sera were positive for SiSVgp70 related AG and/or IC had a median survival time of 2 months after diagnosis versus 7 months for patients with sera negative for such AG and IC. As tested by long‐rank test, survival curves between the two groups are significantly different (P &lt; 0.05). These findings suggest that SiSVgp70 related AG and IC may play an important role in the course of acute leukemia and can provide useful prognostic information.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>6093985</pmid><doi>10.1002/1097-0142(19841215)54:12&lt;2927::AID-CNCR2820541219&gt;3.0.CO;2-3</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1984-12, Vol.54 (12), p.2927-2935
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_81339959
source MEDLINE; Alma/SFX Local Collection
subjects Acute Disease
Adolescent
Adult
Aged
AIDS/HIV
Antigen-Antibody Complex - analysis
Antigens, Viral - analysis
Biological and medical sciences
Hematologic and hematopoietic diseases
Humans
Leukemia - immunology
Leukemia - mortality
Leukemia - therapy
Leukemia, Myeloid - immunology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Middle Aged
Retroviridae - immunology
Sarcoma Virus, Woolly Monkey - immunology
Viral Envelope Proteins - immunology
title Antigens and circulating immune complexes related to the primate retroviral glycoprotein SiSVgp70: Indicators of early mortality in human acute leukemias and chronic myelogenous leukemias in blast crisis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A20%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antigens%20and%20circulating%20immune%20complexes%20related%20to%20the%20primate%20retroviral%20glycoprotein%20SiSVgp70:%20Indicators%20of%20early%20mortality%20in%20human%20acute%20leukemias%20and%20chronic%20myelogenous%20leukemias%20in%20blast%20crisis&rft.jtitle=Cancer&rft.au=Hehlmann,%20R%C3%BCdiger&rft.date=1984-12-15&rft.volume=54&rft.issue=12&rft.spage=2927&rft.epage=2935&rft.pages=2927-2935&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19841215)54:12%3C2927::AID-CNCR2820541219%3E3.0.CO;2-3&rft_dat=%3Cproquest_cross%3E81339959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=81339959&rft_id=info:pmid/6093985&rfr_iscdi=true